Loading
Antibodies, Monoclonal · Journal article
Annals of Medicine · August 7, 2026
Well-designed and adequately powered for the question it asks.
This retrospective cohort study of 216 newly diagnosed AL amyloidosis patients shows that limiting dexamethasone exposure to ≤3 months achieves comparable overall response rates and organ responses to prolonged therapy, while accelerating early deep hematologic response (VGPR/CR) and reducing dexamethasone-related toxicity. The finding is strengthened by multivariable analysis and daratumumab-stratified results but remains subject to selection bias inherent in retrospective design.
Retrospective cohort study. Newly diagnosed systemic light chain amyloidosis (AL) patients. Intervention: Limited dexamethasone duration (≤3 months). Compared with: Prolonged dexamethasone duration (>3 months). n = 216.
Limited Dex (≤3 months) achieved VGPR or better at 6 months in 77.5% vs 56.5% with prolonged Dex (p = 0.001), and CR in 42.2% vs 19.4% (p < 0.001) Overall response rates exceeded 90% at 6 months in both groups, with similar organ responses Among limited Dex patients, daratumumab was associated with higher 6-month CR rates (66.7% vs 30.4%, p < 0.001) and increased CR likelihood on multivariable analysis (HR 4.38, 95% CI 2.44–7.85; p < 0.001)
Specific dexamethasone-related toxicities quantified and compared not detailed in abstract; only statement that toxicities increased after 6 months. Dexamethasone-related toxicities increased after 6 months in the prolonged group
Clinicians treating newly diagnosed AL amyloidosis may consider limiting dexamethasone exposure to ≤3 months to reduce cumulative toxicity while maintaining efficacy, particularly in daratumumab-containing regimens where early deep hematologic response kinetics may be accelerated. Prospective randomization would strengthen this recommendation.
Retrospective cohort study of 216 newly diagnosed AL amyloidosis patients demonstrating that limited dexamethasone (≤3 months) achieves similar overall response rates with faster deep hematologic response and reduced toxicity compared to prolonged exposure, with multivariable adjustment for confounding.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians treating newly diagnosed AL amyloidosis may consider limiting dexamethasone exposure to ≤3 months to reduce cumulative toxicity while maintaining efficacy, particularly in daratumumab-containing regimens where early deep hematologic response kinetics may be accelerated. Prospective randomization would strengthen this recommendation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background. Systemic light chain amyloidosis (AL) is a life-threatening disease in which dexamethasone (Dex) is a core therapy but is limited by cumulative toxicity. The optimal duration of Dex, particularly in the era of daratumumab (Dara)-based regimens, is uncertain.Methods. We retrospectively analyzed 216 newly diagnosed AL amyloidosis patients (2017-2023). Dex exposure was categorized as limited (≤3 months) or prolonged (>3 months) using restricted cubic spline-derived associations with hematologic response kinetics. Outcomes included hematologic and organ response, toxicity, and overall survival.Results. Median Dex duration was 5.5 months and was similar by Dara use. Overall response rates exceeded 90% at 6 months in both Dex groups. Limited Dex was associated with higher rates of early deep hematologic response (VGPR or better 77.5 vs 56.5%, p = 0.001; CR 42.2 vs 19.4%, p < 0.001), reflecting faster response kinetics, while overall response rates were similar. Among patients receiving limited Dex, Dara was associated with higher 6-month CR rates (66.7 vs 30.4%, p < 0.001) and increased likelihood of achieving CR in multivariable analysis (HR 4.38, 95% CI 2.44-7.85; p < 0.001). Organ responses were similar between groups. Dex-related toxicities increased after 6 months, and hospitalization was associated with worse survival.Conclusions. Limiting Dex exposure was associated with preserved efficacy and reduced toxicity. Prolonged Dex was associated with increased toxicity without improving overall hematologic or organ outcomes, supporting limited Dex duration in frontline AL amyloidosis therapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.